The recent spread of Chikungunya fever in China has drawn widespread concern. Since July 2025, local transmission has occurred in Foshan, Guangdong Province. As of July 26, confirmed cases have exceeded 4,800 in Guangdong Province. In addition, the epidemic is still spreading. Relevant cases have also emerged successively in Macao, Beijing and other places, and the risk of imported domestic case persists.
Internationally, WHO experts issued an alert regarding Chikungunya fever-the mosquito-borne disease, reminding all countries to be well-prepared to prevent a large-scale outbreak of the epidemic. According to epidemiology data, the Chikungunya virus transmission has been detected in 119 countries and regions so far. About 5.5 million people are at risk of this mosquito-borne virus, and it may occur a large-scale outbreak, putting pressure on global health system.
Chikungunya fever is an acute mosquito-borne infectious disease transmitted through bites from infected Aedes mosquitoes (primarily Aedes albopictus and Aedes aegypti), Coughing, sneezing, chatting and other daily contacts do not cause infection. Most patients with Chikungunya fever have mild symptoms, such as sudden fever and joint pain. The symptoms of most people will improve within a week. Severe symptoms and deaths are rare, and usually occur in young children and the elderly with underlying diseases. The key in prevention of Chikungunya fever is to immediately cut off transmission routes. People must strictly remove standing water, install screens doors or windows, and use mosquito repellents correctly to prevent mosquito bites in all aspects.
Timely diagnosis is crucial for curbing the epidemic. Qingdao Hightop Biotech offers a CE-certified Chikungunya IgM Rapid Test Kit. This product is simple to operate, delivering results in approximately 15 minutes. It has been widely distributed to Latin America, Africa, Asian-Pacific region and many other areas with high incident of Chikungunya fever epidemic. This kit is ideal for early rapid screening in primary healthcare facilities and emergency scenarios, facilitating precise intervention.
About Hightop
As a high-tech enterprise specializing in in vitro diagnostics, Hightop holds multiple international certifications (including CE, FDA, ANVISA, etc.). Its product portfolio covers multiple fields of seven major methodological platforms, committed to providing accurate and convenient testing tools for global public health.
